GLP-1 Plateau: Why Weight Loss Stalls on Ozempic and Wegovy — and What to Do

What counts as a GLP-1 plateau?

A plateau is a sustained flattening of your weight trend, not a single flat week. Day-to-day body weight swings by 1–2 kg on water, salt, glycogen, and bowel content alone, which is more than the weekly loss most people see on a GLP-1 in any given week. That noise routinely hides real progress and routinely fakes a stall.

The practical definition worth using: your 7-day rolling average weight has not moved meaningfully in three to four consecutive weeks, while your dose and your eating have stayed roughly constant. Anything shorter than three weeks is usually measurement noise rather than a plateau.

When does the GLP-1 plateau usually happen?

The large randomised trials give a clear shape to the curve. In STEP 1 (Wilding et al., NEJM, 2021), 1,961 adults on semaglutide 2.4 mg lost a mean of 14.9% of body weight over 68 weeks versus 2.4% on placebo — and weight loss reached its nadir at week 60, meaning the curve had essentially flattened before the trial ended.

In SURMOUNT-1 (Jastreboff et al., NEJM, 2022), 2,539 adults on tirzepatide over 72 weeks lost a mean of 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) versus 3.1% on placebo, on the trial's primary treatment-regimen estimand. Tirzepatide reaches a higher ceiling than semaglutide, but it still has a ceiling.

STEP 5 (Garvey et al., Nature Medicine, 2022) extended the picture to two years: mean weight change at week 104 was −15.2% with semaglutide versus −2.6% with placebo. That is barely different from STEP 1's 68-week figure — which tells you that on semaglutide, most of the loss happens in roughly the first year, and year two is largely maintenance.

So the honest answer to "when should I expect a plateau?" is: somewhere between month 9 and month 15 for most people, with a great deal of individual variation. A stall at month 3 is a different problem from a stall at month 14.

Why does weight loss stall on a GLP-1?

There are three common explanations, and they are not mutually exclusive.

1. Your titration is not finished. Wegovy reaches its 2.4 mg maintenance dose only at week 16, and tirzepatide steps up over a similar span. A flat month during titration is often a dose that has not caught up with you yet, not a true plateau. This is the single most common misread in the first four months.

2. Energy expenditure fell to meet your intake. This is the physics of it. A smaller body costs fewer calories to move and maintain, so as you lose weight, total energy expenditure declines and the gap between intake and expenditure narrows until it closes. Hall and colleagues (Lancet, 2011) modelled this explicitly: a fixed reduction in energy intake does not produce endless linear weight loss but a curve that flattens into a plateau, with a half-time of roughly one year. Every diet has this property. A GLP-1 changes how much you eat; it does not exempt you from the arithmetic.

3. Intake has drifted back up. Appetite suppression is strongest in the first months and softens as your body adapts to the drug and as you adapt your food choices around it. Softer foods, liquid calories, and grazing all slip past a suppressed appetite easily. This drift is gradual and nearly invisible without a food log — which is precisely why it is so often missed.

Does a plateau mean the medication has stopped working?

Almost never. Holding a substantially lower weight is itself an active effect of the drug, and the evidence for this is unusually clean. In the STEP 1 trial extension (Wilding et al., Diabetes, Obesity and Metabolism, 2022), 327 participants who had lost a mean of 17.3% of body weight at week 68 came off semaglutide. One year later they had regained 11.6 percentage points of that loss, ending at a net −5.6% from baseline at week 120.

Read that the other way round: the flat part of the curve is not the drug doing nothing. It is the drug holding a weight your physiology is actively trying to push back up.

What the evidence supports doing about a plateau

• Confirm it with a rolling average. Three to four weeks of a flat 7-day average, at a stable dose, with stable eating. Anything less is not yet a plateau.
• Check where you are in titration. If you have not reached your maintenance dose, the most likely explanation is simply time. Your prescriber sets the schedule.
• Log food for two weeks, honestly. Not forever — two weeks is usually enough to reveal whether intake has drifted. Most people are surprised by liquid calories and evening grazing.
• Protect muscle: protein and resistance training. Rapid weight loss costs lean mass, and lean mass is metabolically expensive tissue you want to keep. See our guides to preventing muscle loss on GLP-1 medications and the best protein sources when your appetite is suppressed.
• Look at sleep and stress. Both influence appetite and adherence, and both are trackable. A plateau that lines up with a month of five-hour nights is a lead worth following.
• Take the data to your prescriber. A dose adjustment, a switch between agents, or simply confirming you have reached a reasonable set point is a clinical decision — and it is a much better conversation with four weeks of trend data than without.

What not to do

• Do not increase your own dose. Escalating faster than your prescribed schedule mainly buys gastrointestinal side effects, and dosing is not a self-service decision.
• Do not crash your calories. A severe deficit on top of appetite suppression accelerates lean-mass loss and rarely survives contact with real life.
• Do not stop abruptly out of frustration. The STEP 1 extension data above is what stopping looks like.
• Do not judge a plateau on the scale alone. Waist measurements and how clothes fit can keep moving for weeks while body weight sits still — this is common when training is added.

What to track when you plateau

A plateau is a data problem before it is a medical one. The question "has anything actually changed?" is unanswerable from memory and trivially answerable from a log. Four streams are enough:

1. Weight, as a 7-day rolling average — the trend line, not the daily number.
2. Food intake — at least during a two-week check, to catch intake drift.
3. Dose and injection date — so a stall can be lined up against titration steps.
4. Sleep and mood — the two lifestyle variables most likely to move appetite and adherence.

tr8ck's GLP-1 module is built around exactly this: weight trend with a rolling average, dose and side-effect logging tied to your injection day, food, sleep and mood in one place, and correlation analysis that surfaces which of them moved when your weight stopped moving. If you are choosing tools, we compare the options in our guide to the best GLP-1 tracking apps.

The goal is not to make the plateau disappear on demand. It is to walk into your next appointment able to say exactly what changed, and when.

FAQ

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Never start, stop, or change the dose of any medication on your own — discuss it with your prescriber. Clinical trial results are population averages and individual responses vary substantially.